🧠 This Week in Neuroscience: MS Trials, Parkinson’s Targets, Gene Therapy Breakthroughs & More!
Get ready to dive into the latest breakthroughs transforming neuroscience! From massive MS trial completions to promising gene therapy results in Duchenne and Alzheimer’s, we’re breaking down the headlines reshaping brain and nervous system care.
📌 What’s Inside This Week’s Update:
🧠 Casma unveils TRPML1 therapy for Parkinson’s and Gaucher’s
💊 Immunic completes Phase 3 MS trial enrollment (2,200+ patients)
💪 REGENXBIO’s RGX-202 shows Duchenne gains, no serious events
❌ FDA rejects Axsome’s fibromyalgia drug over trial design
🇰🇷 SNUH–UMass team up on rare neurogenetic disorders
🧬 UCSD targets Alzheimer’s via cellular gene therapy
🧪 Denovo forms SAB to guide DB104 for resistant depression
🎗️ 40,000+ flags highlight migraine crisis on National Mall
From gene therapy breakthroughs to cross-continental collaborations, these stories are pushing the boundaries of what’s possible in neuroscience.
✅ Like, share, and subscribe for weekly updates on neuroscience, neurodegeneration, and clinical trials
#Neuroscience #GeneTherapy #BrainHealth #MultipleSclerosis #Parkinsons #Duchenne #Alzheimers #Fibromyalgia #MigraineAwareness #CNSResearch #LucidQuest #Neurodegeneration #ClinicalTrials #NeuroInnovation #BiotechNews #PharmaUpdates